Put New Heart Failure Guidelines in Perspective

Big changes in guidelines will lead to debate about managing heart failure with reduced ejection fraction (HFrEF).

We're used to "triple therapy" for HFrEF...an ACEI or ARB, evidence-based beta-blocker (carvedilol, etc), and aldosterone antagonist (spironolactone, etc)...to reduce hospitalizations and death.

Now sacubitril/valsartan (Entresto) is preferred INSTEAD of an ACEI or ARB when possible...since it prevents hospitalization or CV death in about 1 in 21 patients versus an ACEI.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals